Old Drug,New Trick: Colchicine for Cardiovascular Diseases

Tardif J-C , Kouz S , Waters DD . Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381: 2497–505.

Ridker PM , Everett BM , Thuren T . CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119e1131.

Misra DP . CANTOS - is selective targeting of inflammation in atherosclerosis enough? J R Coll Physicians Edinb 2018; 48: 246–7.

Ridker PM , Everett BM , Pradhan A . Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380: 752–62.

Pandey A , Goyal M . Methotrexate: CIRTified for preventing atherosclerotic events? J R Coll Physicians Edinb 2019; 49: 136–8.

Deftereos SG , Vrachatis DA , Angelidis C . The role of colchicine in treating postoperativeand post-catheter ablation atrial fibrillation. Clin Ther 2018; S0149eS2918.

Nidorf SM , Eikelboom JW , Budgeon CA . Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013; 61: 404e410.

Jin Y , Fu J . Novel insights into the NLRP3 inflammasome in atherosclerosis. J Am Heart Assoc 2019; 8: e012219.

Martinez GJ , Celermajer DS , Patel S . The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 2018; 269: 262–71.

The LoDoCo2 Trial: a randomised controlled trial on the effect of low dose colchicine for secondary prevention of cardiovascular disease in patients with established, stable coronary artery disease. The Australian and New Zealand Clinical Trial Registry. http://www.anzctr.org.au/TrialSearch.aspx?searchTxt1/4LoDoCo2&isBasic¼True (accessed 02/01/20).

Nidorf SM , Thompson PL . Why colchicine should be considered for secondary prevention of atherosclerosis: an overview. Clin Ther 2019; 41: 41–8.